Invex Therapeutics (ASX:IXC) EPS (Diluted) : A$-0.08 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics EPS (Diluted)?

Invex Therapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was A$-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08.

Invex Therapeutics's EPS (Basic) for the six months ended in Dec. 2023 was A$-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08.

Invex Therapeutics's EPS without NRI for the six months ended in Dec. 2023 was A$-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08.

During the past 3 years, the average EPS without NRIGrowth Rate was -21.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Invex Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -21.10% per year. The lowest was -21.10% per year. And the median was -21.10% per year.

Invex Therapeutics EPS (Diluted) Historical Data

The historical data trend for Invex Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics EPS (Diluted) Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

EPS (Diluted)

-0.06

-0.03

-0.05

-0.10

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial				-0.02	-0.03	-0.05	-0.05	-0.03

Competitive Comparison of Invex Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Invex Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's PE Ratio falls into.

Invex Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Invex Therapeutics's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-7.75	-	0)	/	75.154
	=	-0.10

Invex Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.113	-	0)	/	75.154
	=	-0.03

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.08

Invex Therapeutics (ASX:IXC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Invex Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.